Congenital heart block: Clinical features and therapeutic approaches

Lupus

Volumn 16, Issue 8, 2007, Pages 642-646

  Gordons, Patrick A ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Connective tissue diseases; Neonatal lupus; Pregnancy; SSA RO

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAMETHASONE; DEXAMETHASONE; FLUORINATED STEROID; IMMUNOGLOBULIN; RO ANTIBODY;

CLINICAL FEATURE; CONGENITAL HEART BLOCK; CONGESTIVE CARDIOMYOPATHY; DISEASE COURSE; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE HYPERTROPHY; HUMAN; LOW BIRTH WEIGHT; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PSYCHOMOTOR DEVELOPMENT; RECURRENT DISEASE; REVIEW; SIDE EFFECT;

HEART BLOCK; HEART DEFECTS, CONGENITAL; HUMANS; INFANT, NEWBORN; LONG QT SYNDROME;

EID: 34548447668     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203307079041     Document Type: Review

References (49)

1. Lee L, RJ S, Buyon J. Hepatobiliary disease in neonatal lupus: prevalence and clinical characteristics in cases enrolled in a national registry. Arthritis Rheum 2001; 44: 340.
2. Watson R, Kang JE, May M, Hudak M, Kickler T, Provost TT. Thrombocytopenia in the neonatal lupus syndrome. Arch Dermatol 1988; 124: 560-563.
3. Kanagasegar S, Cimaz R, Kurien BT, Brucato A, Scofield RH. Neonatal lupus manifests as isolated neutropenia and mildly abnormal liver functions. J Rheumatol 2002; 29: 187-191.
4. Prendiville JS, Cabral DA, Poskitt KJ, Au S, Sargent MA. Central nervous system involvement in neonatal lupus erythematosus. Pediatr Dermatol 2003; 20: 60-67.
5. Gordon P, Khamashta MA, Rosenthal E et al. Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. J Rheumatol 2004; 31: 2480-2487.
6. Brucato A, Frassi M, Franceschini F et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 2001; 44: 1832-1835.
7. Machado MV, Tynan MJ, Curry PV, Allan LD. Fetal complete heart block. Br Heart J 1988; 60: 512-515.
8. Brucato A, Franceschini F, Gasparini M et al. Isolated congenital complete heart block: longterm outcome of mothers, maternal antibody specificity and immunogenetic background. J Rheumatol 1995; 22: 533-540.
9. Eronen M, Siren MK, Ekblad H, Tikanoja T, Julkunen H, Paavilainen T. Short- and long-term outcome of children with congenital complete heart block diagnosed in utero or as a newborn. Pediatrics 2000; 106: 86-91.
10. Buyon JP, Hiebert R, Copel J et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998; 31: 1658-1666.
11. Gordon PA, Khamashta MA, Hughes GR, Rosenthal E, Simpson J, Sharland G. Early Outcome in anti-Ro antibody associated congenital heart block. Arthritis Rheum 2001; 44: S161.
12. Jaeggi ET, Hamilton RM, Silverman ED, Zamora SA, Hornberger LK. Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. A single institution's experience of 30 years. J Am Coll Cardiol 2002; 39: 130-137.
13. Waltuck J, Buyon JP. Autoantibody-associated congenital heart block: outcome in mothers and children. Ann Intern Med 1994; 120: 544-551.
14. Groves AM, Allan LD, Rosenthal E. Outcome of isolated congenital complete heart block diagnosed in utero. Heart 1996; 75: 190-194.
15. Moak JP, Barron KS, Hougen TJ et al. Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol 2001; 37: 238-242.
16. Karpawich PP, Rabah R, Haas JE. Altered cardiac histology following apical right ventricular pacing in patients with congenital atrioventricular block. Pacing Clin Electrophysiol 1999; 22: 1372-1377.
17. Tantengco MV, Thomas RL, Karpawich PP. Left ventricular dysfunction after long-term right ventricular apical pacing in the young. J Am Coll Cardiol 2001; 37: 2093-2100.
18. Janousek J, Tomek V, Chaloupecky V, Gebauer RA. Dilated cardiomyopathy associated with dual-chamber pacing in infants: improvement through either left ventricular cardiac resynchronization or programming the pacemaker off allowing intrinsic normal conduction. J Cardiovasc Electrophysiol 2004; 15: 470-474.
19. Solti F, Szatmary L, Vecsey T, Renyi-Vamos F Jr, Bodor E. Congenital complete heart block associated with QT prolongation. Eur Heart J 1992; 13: 1080-1083.
20. Garson A Jr, Dick M 2nd, Fournier A et al. The long QT syndrome in children. An international study of 287 patients. Circulation 1993; 87: 1866-1872.
21. Esscher E, Michaelsson M. Q-T interval in congenital complete heart block. Pediatr Cardiol 1983; 4: 121-124.
22. Gordon PA, Khamashta MA, Rosenthal E, Hughes GR. The effect of anti-Ro antibody on the fetus in the abscence of overt congenital heart block. Arthritis Rheum 2002; 46: S318.
23. Cimaz R, Stramba-Badiale M, Brucato A, Catelli L, Panzeri P, Meroni PL. QT interval prolongation in asymptomatic anti-SSA/Ro-positive infants without congenital heart block. Arthritis Rheum 2000; 43: 1049-1053.
24. Costedoat-Chalumeau N, Amoura Z, Lupoglazoff JM et al. Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group. Arthritis Rheum 2004; 50: 3187-3194.
25. Askanase AD, Friedman DM, Copel J et al. Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies. Lupus 2002; 11: 145-151.
26. Gordon PA, Khamashta MA, Hughes GR, Rosenthal E. A normal ECG at birth does not exclude significant congenital cardiac conduction disease associated with maternal anti-Ro antibodies. Rheumatology (Oxford) 2001; 40: 939-940.
27. Nield LE, Silverman ED, Smallhorn JF et al. Endocardial fibroelastosis associated with maternal anti-Ro and anti-La antibodies in the absence of atrioventricular block. J Am Coll Cardiol 2002; 40: 796-802.
28. Julkunen H, Eronen M. The rate of recurrence of isolated congenital heart block: a population-based study. Arthritis Rheum 2001; 44: 487-488.
29. Hughes G. The eradication of congenital heart block. Lupus 2004; 13: 489.
30. Watson RM, Scheel JN, Petri M et al. Neonatal lupus erythematosus. Report of serological and immunogenetic studies in twins discordant for congenital heart block. Br J Dermatol 1994; 130: 342-348.
31. Harley JB, Kaine JL, Fox OF, Reichlin M, Gruber B. Ro (SS-A) antibody and antigen in a patient with congenital complete heart block. Arthritis Rheum 1985; 28: 1321-1325.
32. Cooley HM, Keech CL, Melny BJ, Menahem S, Morahan G, Kay TW. Monozygotic twins discordant for congenital complete heart block. Arthritis Rheum 1997; 40: 381-384.
33. Julkunen H, Eronen M. Long-term outcome of mothers of children with isolated heart block in Finland. Arthritis Rheum 2001; 44: 647-652.
34. Press J, Uziel Y, Laxer RM, Luy L, Hamilton RM, Silverman ED. Long-term outcome of mothers of children with complete congenital heart block. Am J Med 1996; 100: 328-332.
35. Gordon PA, Rosenthal E, Khamashta MA, Hughes GR. Absence of conduction defects in the electrocardiograms of mothers with children with congenital complete heart block. J Rheumatol 2001; 28: 366-369.
36. Tran HB, Cavill D, Buyon JP, Gordon TP. Intravenous immunoglobulin and placental transport of anti-Ro/La antibodies: comment on the letter by Kaaja and Julkunen. Arthritis Rheum 2004; 50: 337-338; author reply 338.
37. Kaaja R, Julkunen H. Prevention of recurrence of congenital heart block with intravenous immunoglobulin and corticosteroid therapy: comment on the editorial by Buyon et al. Arthritis Rheum 2003; 48: 280-281; author reply 281-282.
38. Costedoat-Chalumeau N, Amoura Z, Le Thi Hong D et al. Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block. Ann Rheum Dis 2003; 62: 1010-1012.
39. Lajic S, Wedell A, Bui TH, Ritzen EM, Holst M. Long-term somatic follow-up of prenatally treated children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1998; 83: 3872-3880.
40. Bloom SL, Sheffield JS, McIntire DD, Leveno KJ. Antenatal dexamethasone and decreased birth weight. Obstet Gynecol 2001; 97: 485-490.
41. Zecca E, Papacci P, Maggio L et al. Cardiac adverse effects of early dexamethasone treatment in preterm infants: a randomized clinical trial. J Clin Pharmacol 2001; 41: 1075-1081.
42. Jaeggi ET, Fouron JC, Silverman ED, Ryan G, Smallhorn J, Hornberger LK. Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease. Circulation 2004; 110: 1542-1548.
43. Rosenthal E, Gordon PA, Simpson JM, Sharland GK. Letter regarding article by Jaeggi et al., "transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease". Circulation 2005; 111: e287-288; author reply e287-288.
44. Groves AM, Allan LD, Rosenthal E. Therapeutic trial of sympathomimetics in three cases of complete heart block in the fetus. Circulation 1995; 92: 3394-3396.
45. Robinson BV, Ettedgui JA, Sherman FS. Use of terbutaline in the treatment of complete heart block in the fetus. Cardiol Young 2001; 11: 683-686.
46. Saleeb S, Copel J, Friedman D, Buyon JP. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Arthritis Rheum 1999; 42: 2335-2345.
47. Glickstein J, Buyon J, Kim M, Friedman D. The fetal Doppler mechanical PR interval: a validation study. Fetal Diagn Ther 2004; 19: 31-34.
48. Friedman DM, Kim MY, Copel JA, Davis C, Buyon JP. Utility of cardiac monitoring in fetuses at risk of congenital heart block. The PR interval and dexamethasone evaluation (PRIDE) prospective study. Arthritis Rheum 2006; 54: S689.
49. Sonesson SE, Salomonsson S, Jacobsson LA, Bremme K, Wahren-Herlenius M. Signs of first-degree heart block occur in one-third of fetuses of pregnant women with anti-SSA/Ro 52-kd antibodies. Arthritis Rheum 2004; 50: 1253-1261.